[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Boston Medical Group\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":68},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100548762","effectiveness-of-pelvic-floor-therapy-for-the-management-of-erectile-dysfunction-and-premature-ejaculation-100548762",false,"NCT06425211","Effectiveness of Pelvic Floor Therapy for the Management of Erectile Dysfunction and Premature Ejaculation.","Inclusion Criteria:\n\nOverall:\n\n* Men over 18 years of age\n* Erectile dysfunction or premature ejaculation for at least 6 months\n* Sexual activity with a heterosexual partner at least once a week\n* Signing of informed consent before the start of the study\n\nFor the premature ejaculation group:\n\n* Premature ejaculation according to the International Society of Sexual Medicine (ISSM) criteria\n* Premature Ejaculation Diagnosis Tool (PEDT) questionnaire score greater than 11\n\nFor the erectile dysfunction group:\n\n* Clinical diagnosis of primary erectile dysfunction\n* International Index Erectile Function - Erectile Function domain (IIEF-EF) score less than 26\n\nExclusion Criteria:\n\n* Pharmacological treatment for erectile dysfunction or premature ejaculation in the last 3 months\n* Erection Hardness Score (EHS) greater than 3 for patients with erectile dysfunction\n* History of hypogonadism or suspected hypogonadism due to Aging Males Symptoms (AMS) score greater than 36 for patients with erectile dysfunction\n* History of pelvic radiotherapy\n* Pacemaker or cardiac arrhythmia, epilepsy\n* History of spinal cord trauma or spinal surgeries.\n* Inability to attend therapies or controls\n* Illiteracy or cognitive disability that prevents you from completing the questionnaires\n* Psychiatric, psychological disorders, or cognitive deficiencies\n* Injuries in the area of application of the therapy\n* Active pelvic organ cancer","MALE","18 Years","100 Years",{"count":19,"type":20},66,"ESTIMATED","INTERVENTIONAL",[23],"NA","The objective of this clinical trial is to evaluate the effectiveness of pelvic floor therapy for the management of erectile dysfunction and premature ejaculation in patients with erectile dysfunction and premature ejaculation. The main question to answer is:\n\nWhat is the effectiveness of pelvic floor therapy (electrostimulation, biofeedback, and therapeutic exercise) for the treatment of patients with erectile dysfunction and or premature ejaculation?\n\nPatients will:\n\n* Have an initial consultation of pelvic floor rehabilitation before therapy.\n* Be given pelvic floor therapy.\n* Have a secondary consultation of pelvic floor rehabilitation after therapy.\n\nThree intervention groups will be included: Group 1: Patients with premature ejaculation Group 2: Patients with erectile dysfunction Group 3: Patients with erectile dysfunction and premature ejaculation.",[26,27,28,29],"Erectile Dysfunction","Premature (Early) Ejaculation","Premature Ejaculation","Pelvic Floor; Weak","RECRUITING","2026-01-22",{"date":33,"type":34},"2026-01-23","ACTUAL",{"date":36,"type":34},"2021-10-30",{"date":38,"type":20},"2026-12",{"name":40,"class":41},"Boston Medical Group","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":42},"100548763","phase-3-effectiveness-and-safety-of-tens-therapy-for-premature-ejaculation-100548763","NCT06425224","Effectiveness and Safety of TENS Therapy for Premature Ejaculation","Effectiveness and Safety of Transcutaneous Posterior Tibial Nerve Stimulation Therapy for the Management of Patients With Premature Ejaculation. Phase III Clinical Trial","TENSPE2","Inclusion Criteria:\n\n* Primary premature ejaculation according to the definition of the International Society for Sexual Medicine (ISSM-International Society for Sexual Medicine) (30): a) ejaculation always or almost always occurs within the first minute after penetration, b) inability to delay ejaculation in all or almost all penetrations, c) negative personal consequences are generated, such as stress, annoyance, frustration and\u002For avoidance of sexual intimacy.\n* Age between 18 and 62 years.\n* PEDT score greater than 11.\n* Stable heterosexual relationship for at least 6 months with interest in maintaining it for at least the duration of the study.\n* Sexual activity at least once a week.\n* Minimum chronicity of PD of 6 months.\n* Voluntary participation in the study.\n* Signing of the informed consent prior to participation in the study.\n\nExclusion Criteria:\n\n* IIEF-EF score less than 26.\n* Glaucoma\n* Clinically significant comorbidity: cardiovascular, hepatic, thromboembolic, neurological, locomotor, endocrine, oncological, renal or rheumatological.\n* History of retroperitoneal surgery, radiotherapy or multiple sclerosis.\n* History of mental illness: depression, anxiety, suicidal behavior, bipolar disorder, agoraphobia, dysthymia, social phobia, obsessive-compulsive disorder, post-traumatic stress disorder, psychiatric disorder, reported by the patient or due to the use of a medication for one of these conditions.\n* Consumption of medications that affect ejaculatory control such as psychiatric medications, opioid analgesics, alpha blockers.\n* Treatment for PE in the last 3 months.\n* Treatment for epileptic syndromes or Parkinson's disease.\n* Use of pacemaker or cardiac defibrillator.\n* Skin lesions in the area where the electrodes are placed.\n* Abuse or dependence on psychoactive substances: alcohol, hallucinogenic drugs.\n* Couple who are pregnant or interested in conceiving a pregnancy in the next 3 months.","62 Years",{"count":53,"type":20},129,[55],"PHASE3","The objective of this clinical trial is to evaluate the effectiveness and safety of transcutaneous posterior tibial nerve stimulation therapy in patients with premature ejaculation. The main question to answer is:\n\nCan the effectiveness and safety of transcutaneous electrostimulation of the posterior tibial nerve alone and combined with standard pharmacological treatment be evaluated in men with lifelong premature ejaculation, compared to standard pharmacological treatment with dapoxetine?\n\nPatients will:\n\nBe randomized in acontrolled clinical trial. Patients with a diagnosis of premature ejaculation who attend Boston Medical Group clinics in Mexico City will be included.\n\nBe assigned by randomization to one of three treatment groups:\n\n* Group 1: Tens therapy + dapoxetine placebo on demand.\n* Group 2: Standard treatment (dapoxetine 30 mg as needed) + placebo therapy.\n* Group 3: Tens therapy + standard treatment (dapoxetine 30 mg as needed).",[28,58,59],"Sex Disorder","TEN","2024-05-17",{"date":62,"type":34},"2024-05-22",{"date":64,"type":34},"2022-06-15",{"date":66,"type":20},"2025-06",{"name":40,"class":41},""]